In practice: RECOVERY Trial

In practice: RECOVERY Trial

The Randomised Evaluation of coronavirus disease 2019 (COVID-19) Therapy Trial (RECOVERY) has been the largest COVID-19 treatment study conducted. It provided compelling evidence on the safety and efficacy, or lack thereof, of a multitude of therapies postulated to be of benefit to COVID-19 patients...

Bibliografske podrobnosti
Main Authors:	Horby, P, Peto, L, Landray, M
Drugi avtorji:	Sorenson, RA
Format:	Book section
Jezik:	English
Izdano:	Springer 2024

Podobne knjige/članki

Establishing COVID-19 trials at scale and pace: experience from the RECOVERY trial
od: Peto, L, et al.
Izdano: (2022)

High-dose corticosteroid therapy in COVID-19: the RECOVERY trial – authors' reply
od: Peto, L, et al.
Izdano: (2024)

Making trials part of good clinical care: lessons from the RECOVERY trial
od: Pessoa-Amorim, G, et al.
Izdano: (2021)

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
od: Mafham, M, et al.
Izdano: (2021)

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
od: Landray, M, et al.
Izdano: (2022)

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
od: Horby, P, et al.
Izdano: (2021)

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
od: Horby, P, et al.
Izdano: (2024)

Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
od: Horby, PW, et al.
Izdano: (2023)

Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
od: Abani, O, et al.
Izdano: (2023)

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
od: RECOVERY Collaborative Group, et al.
Izdano: (2022)

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
od: Horby, PW, et al.
Izdano: (2021)

Facilitating participation in clinical trials during pregnancy
od: Vousden, N, et al.
Izdano: (2023)

Methylprednisolone, intravenous immunoglobulin, tocilizimab or anakinra for children with Paediatric Inflammatory Multisystem Syndrome temporally associated with SARS CoV-2 (PIMS-TS, MIS-C) – report from a randomised, controlled, open-label, platform trial
od: Haynes, R, et al.
Izdano: (2023)

Clinical trial results in context: comparison of baseline characteristics and outcomes of 38,510 RECOVERY trial participants versus a reference population of 346,271 people hospitalised with COVID-19 in England
od: Pessoa-Amorim, G, et al.
Izdano: (2024)

Clinical trial results in context: comparison of baseline characteristics and outcomes of 38,510 RECOVERY trial participants versus a reference population of 346,271 people hospitalised with COVID-19 in England
od: Pessoa-Amorim, G, et al.
Izdano: (2024)

Randomised controlled trials for mpox in endemic countries
od: Rojek, A, et al.
Izdano: (2023)

Hydroxychloroquine in hospitalized patients with Covid-19. Reply
od: Horby, P, et al.
Izdano: (2021)

Clinical trial results in context: comparison of baseline characteristics and outcomes of 38,510 RECOVERY trial participants versus a reference population of 346,271 people hospitalised with COVID-19 in England
od: Guilherme Pessoa-Amorim, et al.
Izdano: (2024-06-01)

Analyses of cancer data from three ezetimibe trials.
od: Peto, R, et al.
Izdano: (2008)

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
od: RECOVERY Collaborative Group, et al.
Izdano: (2021)

Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
od: Horby, PW, et al.
Izdano: (2021)

Allocated but not treated: the silent 16% – Authors' reply
od: Horby, P, et al.
Izdano: (2022)

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
od: RECOVERY Collaborative Group, et al.
Izdano: (2022)

GOST: A generic ordinal sequential trial design for a treatment trial in an emerging pandemic.
od: Whitehead, J, et al.
Izdano: (2017)

Corticosteroid therapy for critically ill patients with COVID-19: a structured summary of a study protocol for a prospective meta-analysis of randomized trials
od: Stern, JAC, et al.
Izdano: (2020)

Randomized clinical trials--removing obstacles.
od: Reith, C, et al.
Izdano: (2013)

Randomized clinical trials--removing obstacles.
od: Reith, C, et al.
Izdano: (2013)

Practical heat recovery/
od: 424199 Boyen, John L.
Izdano: (1975)

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
od: RECOVERY Collaborative Group, et al.
Izdano: (2024-01-01)

Increasing the use of mobile technology-derived endpoints in clinical trials.
od: Herrington, W, et al.
Izdano: (2018)

Ezetimibe/simvastatin (vytorin) in heart and renal protection: The SHARP trial
od: Alexander, W, et al.
Izdano: (2011)

Molnupiravir or nirmatrelvir-ritonavir versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
od: RECOVERY Collaborative Group, et al.
Izdano: (2024)

Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)—A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics
od: Landray, M, et al.
Izdano: (2017)

Correction: GOST: A generic ordinal sequential trial design for a treatment trial in an emerging pandemic.
od: John Whitehead, et al.
Izdano: (2018-04-01)

Accelerating clinical trials: time to turn words into action
od: Landray, MJ, et al.
Izdano: (2023)

Misleading associations between cholesterol and vascular outcomes in dialysis patients: the need for randomized trials.
od: Baigent, C, et al.
Izdano: (2007)

Statin therapy in kidney disease populations: potential benefits beyond lipid lowering and the need for clinical trials.
od: Baigent, C, et al.
Izdano: (2004)

Overcoming the barriers to better evidence generation from clinical trials
od: Kehoe, L, et al.
Izdano: (2024)

Realising the full potential of data-enabled trials in the UK: a call for action
od: Sydes, M, et al.
Izdano: (2021)

Randomised controlled trials for Ebola: practical and ethical issues.
od: Adebamowo, C, et al.
Izdano: (2014)